Scholarlink

<p>Multiple factors affect the absorption of orally administered levodopa, the gold standard for the treatment of Parkinson’s disease (PD). <i>Enterococcus faecalis</i> (<i>E. faecalis</i>) expresses the enzyme tyrosine decarboxylase (tyrDC), which metabolizes levodopa into dopamine and thereby may influence its absorption in patients with PD. This study investigated the association between fecal <i>E. faecalis</i> and <i>tyrDC</i> gene levels and the pharmacokinetics of orally administered levodopa in 21 patients with PD. Our results revealed a significant association between elevated fecal levels of <i>E. faecalis</i> and <i>tyrDC</i> gene levels and reduced peak plasma levodopa concentrations. Additionally, among patients receiving levodopa-carbidopa intestinal gel treatment, strong positive correlations were observed between <i>E. faecalis</i> and <i>tyrDC</i> gene levels in fecal samples and those from the tip of the jejunal tube. Further prospective studies are required to explore the potential role of gut microbiota as a therapeutic target in patients with PD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of Enterococcus faecalis and tyrosine decarboxylase gene levels with levodopa pharmacokinetics in Parkinson’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月18日

查看全文
  • Noriyuki Miyaue,
  • Haruto Yamamoto,
  • Shuang Liu,
  • Yuko Ito,
  • Yuki Yamanishi,
  • Rina Ando,
  • Yasuyuki Suzuki,
  • Masaki Mogi,
  • Masahiro Nagai

摘要

Multiple factors affect the absorption of orally administered levodopa, the gold standard for the treatment of Parkinson’s disease (PD). Enterococcus faecalis (E. faecalis) expresses the enzyme tyrosine decarboxylase (tyrDC), which metabolizes levodopa into dopamine and thereby may influence its absorption in patients with PD. This study investigated the association between fecal E. faecalis and tyrDC gene levels and the pharmacokinetics of orally administered levodopa in 21 patients with PD. Our results revealed a significant association between elevated fecal levels of E. faecalis and tyrDC gene levels and reduced peak plasma levodopa concentrations. Additionally, among patients receiving levodopa-carbidopa intestinal gel treatment, strong positive correlations were observed between E. faecalis and tyrDC gene levels in fecal samples and those from the tip of the jejunal tube. Further prospective studies are required to explore the potential role of gut microbiota as a therapeutic target in patients with PD.